Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2019

Shelley Wood

December 31, 2019

News Daily News

NOBLE at 5 Years: New Data Favor CABG for Left Main Disease

Todd Neale

December 23, 2019

News Daily News

FDA Approves Icosapent Ethyl for Reducing CVD Events

Michael O'Riordan

December 13, 2019

News Conference News AHA 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Yael L. Maxwell

November 21, 2019

News Conference News AHA 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

Yael L. Maxwell

November 17, 2019

News Opinion Off Script AHA 2019

Off Script: Will ISCHEMIA Answer Our Most Pressing Questions?

Ajay Kirtane, MD, SM

November 12, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2019

Todd Neale

October 31, 2019

News Daily News

FDA Gives Rivaroxaban Another VTE-Related Indication

Todd Neale

October 14, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Conference News TCT 2019

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Michael O'Riordan

September 30, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

News Conference News ESC 2019

Another Step Forward for Genotype-Guided Prescribing After PCI: POPular Genetics

Yael L. Maxwell

September 03, 2019

News Conference News ESC 2019

Prasugrel Bests Ticagrelor in ACS Patients Heading to PCI: ISAR-REACT 5

Shelley Wood

September 01, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Conference News ESC 2019

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

Michael O'Riordan

August 31, 2019

News Conference News ESC 2019

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Yael L. Maxwell

August 31, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

Advertisement

TCTMD’s Top 10 Most Popular Stories for December 2019

NOBLE at 5 Years: New Data Favor CABG for Left Main Disease

FDA Approves Icosapent Ethyl for Reducing CVD Events

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

Off Script: Will ISCHEMIA Answer Our Most Pressing Questions?

TCTMD’s Top 10 Most Popular Stories for October 2019

FDA Gives Rivaroxaban Another VTE-Related Indication

Recurrent Events Common Among Young Patients With CAD

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Another Step Forward for Genotype-Guided Prescribing After PCI: POPular Genetics

Prasugrel Bests Ticagrelor in ACS Patients Heading to PCI: ISAR-REACT 5

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content